Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer

Slides:

Advertisements

Similar presentations

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project Fred R. Hirsch, MD, PhD,

Advertisements

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Chee Khoon Lee, PhD, Johnathan Man, M. B. B. S

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD Journal of Thoracic Oncology

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

Antibody Independent Microfluidic Cell Capture of Circulating Tumor Cells for the Diagnosis of Cancer Eric Lim, MB, ChB, MD, MSc, FRCS, Andee Tay, BSc,

Prognostic Significance of PD-L1 in Patients with Non–Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases Jong-Mu Sun, MD, Wei.

SC17.02 Lung Cancer in China: Challenges and Perspectives

Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non–Small Cell Lung Cancer Chao Li, MD, PhD,

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project Fred R. Hirsch, MD, PhD,

Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG.

OPG/RANKL/RANK Pathway as a Therapeutic Target in Cancer

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review Swati Kulkarni, MD, Emily T. Vella,

PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer Hui Yu, MD, PhD, Cory Batenchuk, PhD,

Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer Hidenobu Ishii, MD,

Tumor Regression and Positional Changes in Non-small Cell Lung Cancer During Radical Radiotherapy Gerald Lim, MD, Andrea Bezjak, MD, CM, MSc, Jane Higgins,

Megan B. Barnet, BS, M. B. B. S. , Sandra O’Toole, PhD, Lisa G

Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint.

Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non–Small Cell Lung Cancer Suzanne Jenkins, DPhil, James C-H.

Electronic Updates for JTO Readers

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non–Small Cell Lung Cancer Patients Treated with Anti–PD-1/PD-L1.

Takehito Shukuya, MD, PhD, David P. Carbone, MD, PhD

Early Response to Platinum-Based First-Line Chemotherapy in Non-small Cell Lung Cancer May Predict Survival Bhawna Sirohi, MBBS, DCH, Sue Ashley, BSc,

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer Peter Goldstraw, MB, FRCS, John J. Crowley, PhD

Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma Steven C. Kao, PhD, Yuen Yee Cheng, PhD,

Critical Appraisal of Programmed Death Ligand 1 Reflex Diagnostic Testing: Current Standards and Future Opportunities Matthew P. Humphries, PhD, Stephen.

LKB1 Regulated Pathways in Lung Cancer Invasion and Metastasis

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

“Pseudoprogression” of Pulmonary Pleomorphic Carcinoma during Nivolumab Therapy Kentaro Ito, MD, Osamu Hataji, MD, Koji Katsuta, MD, Tetsu Kobayashi,

Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline J Noble,

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

The Applicability of the Proposed IASLC Staging Revisions to Small Cell Lung Cancer (SCLC) with Comparison to the Current UICC 6th TNM Edition Sai-Hong.

Geographic Variation in EGFR Mutation Frequency in Lung Adenocarcinoma May Be Explained by Interethnic Genetic Variation Lars Soraas, MSc, Justin Stebbing,

Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial Kenneth S. Thress, PhD, Vivien.

Elizabeth B. Gottlin, PhD, Rex C. Bentley, MD, Michael J

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

LAG-3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD- 1/PD-L1 and Tumor-Infiltrating Lymphocytes Yayi He, MD, PhD, Hui.

Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

The Prognostic Significance of Focal Adhesion Kinase Expression in Stage I Non– Small-Cell Lung Cancer Grace K. Dy, MD, Lourdes Ylagan, MD, Saraswati.

Pembrolizumab-Induced Encephalopathy: A Review of Neurological Toxicities with Immune Checkpoint Inhibitors Sophie Feng, M.B.B.S., Jermaine Coward, PhD,

A Different Method in Diagnosis of Multiple Primary Lung Cancer

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Vamsidhar Velcheti, MD Journal of Thoracic Oncology

ALK Translocation in Non-small Cell Lung Cancer with Adenocarcinoma and Squamous Cell Carcinoma Markers Samuel J. Klempner, MD, David W. Cohen, MD, Daniel.

A Primer on Health Economic Evaluations in Thoracic Oncology

Clinical Relevance of Our Multimodality Prognostic Score

Toni-Maree Rogers, BMLS, Prudence A

Immune-Modulating Vaccines in Non-small Cell Lung Cancer

Phase I Study of Lenalidomide in Solid Tumors

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non– Small Cell Lung Cancer Emily Castellanos, MD, Emily Feld, MD, Leora.

Should Never-Smokers at Increased Risk for Lung Cancer Be Screened?

The Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Lung Cancer: Still Following the Right TRAIL? Emmet E. McGrath, MB, PhD Journal of Thoracic.

Manoj P. Menon, MD, MPH, Keith D. Eaton, MD, PhD

Ethnic Differences in the Management of Lung Cancer in New Zealand

European Lung Cancer Conference (ELCC) 2016 Organisation

SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non–Small Cell Lung Cancer and.

Tumor Lysis Syndrome in Limited-Stage Small-Cell Lung Cancer

Regression of Paraneoplastic Rash after Lung Cancer Chemotherapy

A B3 Type-Thymoma in a 7-Year-Old Child with Myasthenia Gravis

Rogerio C. Lilenbaum, MD, John Cashy, PhD, Thomas A

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

A Review of First-Line Treatment for Small-cell Lung Cancer

Robert Comis, MD, The Passing of a “Lung Man”

Reply to “Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non–Small Cell Lung Cancer: Methodological Issues” Boris Sepesi,

Presentation transcript:

Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer Shona Hendry, M.B.B.S., David J. Byrne, BSc, Gavin M. Wright, PhD, Richard J. Young, MSc, Sue Sturrock, BSc, Wendy A. Cooper, PhD, Stephen B. Fox, DPhil Journal of Thoracic Oncology Volume 13, Issue 3, Pages 367-376 (March 2018) DOI: 10.1016/j.jtho.2017.11.112 Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Representative tumor microarray core stained with the programmed death ligand 1 immunohistochemical assays 22C3, 28-8, SP142, and SP263. Journal of Thoracic Oncology 2018 13, 367-376DOI: (10.1016/j.jtho.2017.11.112) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 (A) Tumor cell scores for each programmed death ligand 1 immunohistochemical assay. (B) Immune cell scores for each programmed death ligand 1 immunohistochemical assay. Cases with no staining by all four antibodies are not shown. Journal of Thoracic Oncology 2018 13, 367-376DOI: (10.1016/j.jtho.2017.11.112) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 3 Scatter plots showing pairwise comparisons of the percentage tumor cell staining between the four programmed death ligand 1 immunohistochemical assays (N = 355), including regression line with 95% confidence intervals. Journal of Thoracic Oncology 2018 13, 367-376DOI: (10.1016/j.jtho.2017.11.112) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions